Rifampicin resistance in Mycobacterium tuberculosis in Iran: a two-centre study

F. Bahraminia; M. Zangiabadian; M.J. Nasiri; M. Fattahi; M. Goudarzi; R. Ranjbar; A.A. Imani Fooladi

New Microbes and New Infections (Jul 2021)

Rifampicin resistance in Mycobacterium tuberculosis in Iran: a two-centre study

F. Bahraminia,
M. Zangiabadian,
M.J. Nasiri,
M. Fattahi,
M. Goudarzi,
R. Ranjbar,
A.A. Imani Fooladi

Affiliations

F. Bahraminia: Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
M. Zangiabadian: Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
M.J. Nasiri: Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
M. Fattahi: Regional Tuberculosis Reference Laboratory, Tehran University of Medical Sciences, Tehran, Iran
M. Goudarzi: Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
R. Ranjbar: Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
A.A. Imani Fooladi: Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran; Corresponding author: A.A. Imani Fooladi, Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Journal volume & issue: Vol. 42
p. 100909

Abstract

Read online

Multidrug-resistant tuberculosis remains a challenge. In this study, we investigated the incidence of rifampicin (RIF) resistance in Mycobacterium tuberculosis in a large number of pulmonary specimens.A two-center study in Tehran, the capital of Iran, was performed with 6624 pulmonary samples of patients with tuberculosis (TB) who were subjected to detection of RIF-resistant TB by GeneXpert MTB/RIF assay between May 2014 and July 2018. Conventional drug susceptibility testing was performed to confirm the results.Xpert MTB/RIF identified a total of 96 positives for M. tuberculosis, of which 5 (5.3%) samples were found to be RIF-resistant TB. All RIF-resistant and sensitive isolates detected by GeneXpert were phenotypically confirmed by drug susceptibility testing.These results indicated that the Xpert MTB/RIF test can be used as a rapid diagnostic method and can potentially decrease the morbidity associated with diagnostic delay and mistreatment.

Published in New Microbes and New Infections

ISSN: 2052-2975 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Infectious and parasitic diseases
Website: https://www.sciencedirect.com/journal/new-microbes-and-new-infections

About the journal

Abstract

Keywords